Andrew Devine
University of St Andrews
4 Papers
Andrew Devine is an academic researcher from University of St Andrews. The author has contributed to research in topics: Chemistry & Medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
The Role of Cytochrome P450 AbyV in the Final Stages of Abyssomicin C Biosynthesis
Andrew Devine,Alice E. Parnell,Catherine R. Back,Nicholas R. Lees,Samuel T Johns,Ainul Zura Zulkepli,R. Barringer,Katja Zorn,James E. M. Stach,Matthew P. Crump,Martin A. Hayes,Marc W. van der Kamp,Paul R. Race,Christine L. Willis +13 more
TL;DR: In this paper , the X-ray crystal structure of AbyV has been determined, which in combination with molecular dynamics simulations provides a structural framework for their functional data, and demonstrates the power of combining selective carbon-13 labeling with NMR spectroscopy as a sensitive tool to interrogate enzyme-catalysed reactions in vitro with no need for purification.
13
CELA1 Mediates Progressive Emphysema in Alpha-1 Antitrypsin Deficiency
Andrew Devine,N. Smith,Rashika Joshi,Qiang Fan,Michael T. Borchers,Geremy Clair,Joshua N. Adkins,Brian M. Varisco +7 more
TL;DR: In this paper , the role of chymotrypsin-like elastase 1 (CELA1) in emphysema development in this genetic model of AAT-deficiency following tracheal lipopolysacharide (LPS), 8 months of cigarette smoke (CS) exposure, aging, and a low-dose porcine pancreatic elastases (LD-PPE) model was investigated.
Enzymatic Fluorination of Biotin and Tetrazine Conjugates for Pretargeting Approaches to Positron Emission Tomography Imaging.
TL;DR: The fluorinase‐mediated transhalogenation of ClDA substrates to 5′‐fluoro‐5′‐deoxyadenosine (FDA) products and a protocol to avoid radiolytically promoted oxidation of biotin during the synthesis of [18F]FDA‐PEG‐biotin were developed.
Chymotrypsin-like Elastase-1 Mediates Progressive Emphysema in Alpha-1 Antitrypsin Deficiency.
Andrew Devine,N. Smith,Rashika Joshi,Qiang Fan,Michael T. Borchers,Geremy Clair,Joshua N. Adkins,Brian M. Varisco +7 more
- 01 Aug 2023
TL;DR: While anti-CELA1 therapies could potentially be used to prevent emphysema progression in AAT deficiency after smoking cessation, an understanding of why and how CS exacerbates emphySEma in Cela1 deficiency and whether AAT replacement therapy mitigates this effect is needed first.